体能状态与中性粒细胞-淋巴细胞比值对仑伐替尼治疗碘难治性分化型甲状腺癌疗效的相关性
该回顾性分析基于SELECT研究,评估基线ECOG PS和NLR对仑伐替尼治疗RR-DTC患者预后的影响。结果显示基线ECOG PS为0或NLR≤3与更好的PFS、OS和ORR相关。
要点
- 基线ECOG PS 0较1者PFS、OS及ORR均显著改善。
- 基线NLR≤3较>3者PFS和OS显著改善,ORR有改善趋势。
- 基线ECOG PS和NLR可能为RR-DTC仑伐替尼疗效的预后标志。
核心结论
- 较低的ECOG PS和NLR可能为RR-DTC患者接受仑伐替尼治疗获得更好疗效提供预后价值。
研究设计与样本
- 回顾性分析SELECT研究,纳入随机接受仑伐替尼的RR-DTC患者,按基线ECOG PS(0或1)或基线NLR(≤3或>3)分组。
主要发现
- 基线ECOG PS 0较1者PFS显著改善(HR 0.52;95%CI 0.35-0.77;p=0.001)。
- 基线ECOG PS 0较1者OS显著改善(HR 0.42;95%CI 0.26-0.69;p=0.0004)。
- 基线ECOG PS 0较1者ORR显著改善(OR 3.51;95%CI 2.02-6.10;p<0.0001)。
- 基线NLR≤3较>3者PFS显著改善(HR 0.43;95%CI 0.29-0.65;p<0.0001)。
- 基线NLR≤3较>3者OS显著改善(HR 0.48;95%CI 0.29-0.78;p=0.0029),ORR有改善趋势(OR 1.57;95%CI 0.94-2.64;p=0.08)。
关键数值与推荐
- 基线ECOG PS分为0或1。
- 基线NLR分为≤3或>3。
临床怎么用
- 在RR-DTC患者启动仑伐替尼治疗前,可评估基线ECOG PS和NLR以辅助预后分层。
局限性
- 为回顾性分析,仅纳入SELECT研究中随机接受仑伐替尼的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Radioiodine-refractory differentiated thyroid cancer (RR-DTC) has a low 10-year patient-survival rate and is challenging to treat. Lenvatinib is a multikinase inhibitor approved for the treatment of RR-DTC. This study aims to assess Eastern Cooperative Oncology Group performance status (ECOG PS) and neutrophil-to-lymphocyte ratio (NLR) as prognostic markers for patients with RR-DTC treated with lenvatinib. Methods: In this retrospective analysis of the Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid (SELECT), patients randomly assigned to receive lenvatinib were classified according to baseline ECOG PS (0 or 1) or baseline NLR (≤3 or >3). The effects of baseline ECOG PS and NLR on progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were evaluated. In addition, the effects of baseline ECOG PS on the change in diameter of target lesions and correlations between baseline NLR and the sums of the diameters of target lesions were calculated. Results: Among patients who received lenvatinib, patients with a baseline ECOG PS of 0 had statistically improved PFS (hazard ratio [HR] 0.52; 95% confidence interval [CI 0.35-0.77]; p = 0.001), OS (HR 0.42 [CI 0.26-0.69]; p = 0.0004), and ORR (odds ratio [OR] 3.51 [CI 2.02-6.10]; p < 0.0001) compared with patients with a baseline ECOG PS of 1. Patients who received lenvatinib with a baseline NLR ≤3 also had improved PFS (HR 0.43 [CI 0.29-0.65]; p < 0.0001) and OS (HR 0.48 [CI 0.29-0.78]; p = 0.0029) versus patients with a baseline NLR >3. Moreover, patients with a baseline NLR ≤3 had a trend toward increased ORR (OR 1.57 [CI 0.94-2.64]; p = 0.08) compared with patients with a baseline NLR >3. Treatment-emergent adverse events were generally similar among patients who received lenvatinib, irrespective of patients' ECOG PS at baseline. Conclusion: Lower ECOG PS and NLR may provide prognostic value for improved efficacy in patients with RR-DTC. ClinicalTrials.gov no. NCT01321554.
引用
- Taylor MH, Takahashi S, Capdevila J, et al. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. Thyroid. 2021. PMID: 33637020. doi:10.1089/thy.2020.0779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。